Health Condition 1: H15-H22- Disorders of sclera, cornea, iris and ciliary body
Conditions
Interventions
Intervention1: Regular drugs plus probiotic therapy: Topical corticosteroid Prednisolone acetate 1% eye drops q2hourly for the first one week and then tapered over the next 6 weeks by one drop less ev
Sponsors
Hyderabad Eye Research Foundation
Eligibility
Inclusion criteria
Inclusion criteria: 1. Ability to give informed consent for participation. 2. Males or females greater than or equal to 18 years of age. 3. Patients and controls should not have received antibiotics, pro- or prebiotic treatment for at least three months prior to sample collection. 4. Patients with Non-granulomatous anterior uveitis. 5. Presenting AC reaction greater than or equal to grade 2. 6. Onset less than or equal to 2 weeks. 7. HLA-B27 positive 8. All cohorts are matched for diet, age, gender, ethnicity etc. 9. Rule out infectious etiology
Exclusion criteria
Exclusion criteria: 1. Posterior segment inflammation more than spillover vitritis. 2. Active infectious uveitis 3. Lens induced uveitis 4. Non-HLA-B27 associated uveitis 5. Any significant systemic or ocular disease that could compromise the uveitis in the study eye. These include, but are not limited to: a. Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR). b. Wet age-related macular degeneration. c. Myopic degeneration with active sub-foveal choroidal neovascularization. d. Uncontrolled glaucoma, intraocular pressure of > 21 mm Hg while on medical therapy, or chronic hypotony ( 6. Any implantable corticosteroid-eluting device (e.g. Ozurdex, I-vation, triamcinolone acetonide [TA] intravitreal implant) in the study eye within the past 90 days. 7. Any of the following treatments within 90 days prior to enrollments: a. Intravitreal injections (including steroids and anti-vascular endothelial growth factors); b. Posterior subtenon steroids. 8. Free from antibiotic and systemic immunosuppressant use (three months prior to presentation and during the course of study).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. To demonstrate that concurrent probiotic therapy during standard treatment for HLA-B27 associated AU facilitates faster remission of clinical inflammation. b. To demonstrate that probiotic therapy helps in prevention of relapse in patients with quiescent HLA-B27 associated AU.Timepoint: 1 Week, 4 Weeks, 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor pro-inflammatory cytokines in serum of patients prior to and after probiotic therapyTimepoint: 1 Week, 4 Weeks, 8 weeks | — |
Countries
India
Contacts
Public ContactDr Sisinthy Shivaji
LV Prasad Eye Institute
Outcome results
None listed